Back to All Services
Our Services
Health Economics Research
At Medicys we partner with, and are preferred suppliers to, many leading health economics firms who focus on measuring and valuing the outcomes of healthcare interventions and who seek to understand how to navigate regulatory frameworks and Health Technology Assessment processes.
Specifically, our pricing and market access specialists recruit, interview and report on our network of local, regional and national payers (and ex payers) and Payer Advising Key Opinion Leaders (PA-KOLs) on topics such as:
- Economic Evaluation
- Cost of illness
- Cost comparison, effectiveness, utility and benefit
- Thresholds and opportunity costs
- Value driven healthcare systems
- Health Policy and Regulatory frameworks
- Approval and labelling
- Pricing Policy and pricing Schemes
- Reimbursement and access
- Insurance systems and national healthcare
- Public spending and national health expenditures
- Procurement systems
- Risk sharing approaches
- Health Technology Assessment
- Systems and structure
- Value framework and dossier format
- Decisions and deliberative processes
Our projects in this discipline usually take the form of Web Assisted Telephone Depth Interviews (WATDIs), online groups or advisory boards (digital or in person).
Related Work
See all Work
health economics research
To understand the usage of real world evidence data and information in order to help with monitoring drug outcomes and costs
health economics research
Clostridioides Difficile Infection
Gain a better understanding of acceptable pricing and of the process and evidence requirements to obtain optimal market access for a potential adult vaccine for the prevention of primary Clostridioides Difficile Infection (CDI) in individuals ≥50 years of age
health economics research
+2
Key Opinion Leaders (KOLs), respiratory physicians
Talking to key decision makers in the area of respiratory infections, specifically SARS-CoV2, respiratory pandemics and also infectious rhinitis and rhinosinusitis. Understand views on the treatment and management of respiratory infections, and the impact that a new treatment may have on this therapeutic area in the future. Discuss the potential pricing and reimbursement implications a new product may have on this therapy area
health economics research
Methicillin-resistant Staphylococcus aureus
+2
Infectious disease physicians, heads of department
To assess some TPPs and to determine keys to success, utilization and payer reactions and pricing
Request a quote
